1298 results
Keyword Isopuramin 3% Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Aldara
imiquimod, Condylomata Acuminata; Keratosis; Keratosis, Actinic; Carcinoma, Basal Cell
Date of authorisation: 18/09/1998, Revision: 30, Authorised, Last updated: 20/03/2023patients compared with 0 to 3% in the placebo group. There … patients compared with 0 to 3% in the placebo group. There … -
List item
Human medicine European public assessment report (EPAR): Simbrinza
brinzolamide, brimonidine tartrate, Ocular Hypertension; Glaucoma, Open-Angle
Date of authorisation: 18/07/2014, Revision: 10, Authorised, Last updated: 19/12/2022taste disturbances) in about 3% of patients. For the full … taste disturbances) in about 3% of patients. For the full … -
List item
Human medicine European public assessment report (EPAR): Pegasys
peginterferon alfa-2a, Hepatitis C, Chronic; Hepatitis B, Chronic
Date of authorisation: 20/06/2002, Revision: 45, Authorised, Last updated: 07/11/2022after 24 weeks, compared with 3% of those not given any treatment … -
List item
Human medicine European public assessment report (EPAR): Hetlioz
tasimelteon, Sleep Disorders, Circadian Rhythm
Date of authorisation: 03/07/2015,
, Revision: 9, Authorised, Last updated: 11/10/2022
treatment, compared with around 3% of patients on placebo (1 … treatment, compared with around 3% of patients on placebo (1 … -
List item
Human medicine European public assessment report (EPAR): Bonviva
ibandronic acid, Osteoporosis, Postmenopausal
Date of authorisation: 23/02/2004, Revision: 29, Authorised, Last updated: 02/08/2022the monthly tablets and by 3% with the injections, compared … the monthly tablets and by 3% with the injections, compared … -
List item
Human medicine European public assessment report (EPAR): Tremfya
Guselkumab, Psoriasis
Date of authorisation: 10/11/2017, Revision: 8, Authorised, Last updated: 22/07/2022receiving adalimumab and under 3% (11 out of 422) receiving … receiving adalimumab and under 3% (11 out of 422) receiving … -
List item
Human medicine European public assessment report (EPAR): Dexdor
Dexmedetomidine hydrochloride, Conscious Sedation
Date of authorisation: 15/09/2011, Revision: 15, Authorised, Last updated: 14/07/2022higher dose compared with 3% of patients receiving placebo … -
List item
Human medicine European public assessment report (EPAR): Baraclude
Entecavir, Hepatitis B, Chronic
Date of authorisation: 26/06/2006, Revision: 27, Authorised, Last updated: 11/02/2022and nausea (feeling sick, 3%). For the full list of side … and nausea (feeling sick, 3%). For the full list of side … -
List item
Human medicine European public assessment report (EPAR): Tecfidera
dimethyl fumarate, Multiple Sclerosis
Date of authorisation: 30/01/2014, Revision: 27, Authorised, Last updated: 20/04/2023brain, compared with around 3% of children in the interferon … brain, compared with around 3% of children in the interferon … -
List item
Human medicine European public assessment report (EPAR): Xarelto
rivaroxaban, Arthroplasty, Replacement; Venous Thromboembolism
Date of authorisation: 30/09/2008, Revision: 39, Authorised, Last updated: 23/02/2023recurrent VTE, compared with 3% (5 out of 165) of those treated … recurrent VTE, compared with 3% (5 out of 165) of those treated … -
List item
Human medicine European public assessment report (EPAR): Kyntheum
brodalumab, Psoriasis
Date of authorisation: 17/07/2017, Revision: 6, Authorised, Last updated: 10/01/2023after 12 weeks, compared with 3% of patients given placebo … after 12 weeks, compared with 3% of patients given placebo … -
List item
Human medicine European public assessment report (EPAR): Cufence
trientine dihydrochloride, Hepatolenticular Degeneration
Date of authorisation: 25/07/2019, Revision: 5, Authorised, Last updated: 08/11/2022worsening liver symptoms and 3% with worsening neurological … worsening liver symptoms and 3% with worsening neurological … -
List item
Human medicine European public assessment report (EPAR): Zinforo
Ceftaroline fosamil, Community-Acquired Infections; Skin Diseases, Infectious; Pneumonia
Date of authorisation: 22/08/2012, Revision: 26, Authorised, Last updated: 22/07/2022Zinforo (seen in more than 3% of patients) are diarrhoea … -
List item
Human medicine European public assessment report (EPAR): Forsteo
teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 10/06/2003, Revision: 24, Authorised, Last updated: 20/01/2022the spine, compared with 3% in those receiving alendronate … the spine, compared with 3% in those receiving alendronate … -
List item
Human medicine European public assessment report (EPAR): Wegovy (updated)
semaglutide, Obesity; Overweight
Date of authorisation: 06/01/2022,
, Revision: 3, Authorised, Last updated: 09/06/2023
their weight compared with a 3% loss in people who had placebo … their weight compared with a 3% loss in people who had placebo … -
List item
Human medicine European public assessment report (EPAR): Synflorix (updated)
Pneumococcal polysaccharide serotype 23F, Pneumococcal polysaccharide serotype 4, Pneumococcal polysaccharide serotype 5, Pneumococcal polysaccharide serotype 6B, Pneumococcal polysaccharide serotype 7F, Pneumococcal polysaccharide serotype 9V, Pneumococcal polysaccharide serotype 1, Pneumococcal polysaccharide serotype 14, Pneumococcal polysaccharide serotype 18C, Pneumococcal polysaccharide serotype 19F, Pneumococcal Infections; Immunization
Date of authorisation: 29/03/2009, Revision: 36, Authorised, Last updated: 24/05/2023given Synflorix compared with 3% (304 out of over 10,000 … Synflorix compared with 3% (304 out of over 10,000 … -
List item
Human medicine European public assessment report (EPAR): Revolade (updated)
Eltrombopag, Purpura, Thrombocytopenic, Idiopathic
Date of authorisation: 11/03/2010, Revision: 31, Authorised, Last updated: 16/05/202363) compared with around 3% (1 out of 29) of those who … 63) compared with around 3% (1 out of 29) of those who … -
List item
Human medicine European public assessment report (EPAR): Soliris
Eculizumab, Hemoglobinuria, Paroxysmal
Date of authorisation: 20/06/2007,
, , Revision: 34, Authorised, Last updated: 18/04/2023
around 22 months on average, 3% of patients treated with … -
List item
Human medicine European public assessment report (EPAR): Stelara
Ustekinumab, Psoriasis; Arthritis, Psoriatic; Crohn Disease; Colitis, Ulcerative
Date of authorisation: 15/01/2009, Revision: 42, Authorised, Last updated: 18/01/2023weeks, compared with around 3% of the patients receiving … -
List item
Human medicine European public assessment report (EPAR): Nucala
Mepolizumab, Asthma
Date of authorisation: 01/12/2015, Revision: 18, Authorised, Last updated: 11/10/2022vasculitis) compared with 3% (2 out of 68) of patients … -
List item
National expert: Martin Hohenegger, Austrian Agency for Health and Food Safety (updated)
- Declaration of interests - 41.93 KB | PDF
- Curriculum Vitae - 27.38 KB | PDF
related Chloroprocaine 3% Gel Eye Drops Local anesthesia … -
List item
Orphan designation: 2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine) for: Treatment of anaplastic thyroid cancer
Date of designation: 21/07/2021, Withdrawn, Last updated: 21/07/2021and represents only 1 to 3% of all thyroid cancers. Signs … -
List item
Press release: European Medicines Agency gives second positive opinion for a paediatric-use marketing authorisation
CHMP, Last updated: 21/02/2014shrink spontaneously. Around 3% to 10% of children are affected … shrink spontaneously. Around 3% to 10% of children are … -
List item
Orphan designation: Overview (updated)
Last updated: 11/05/2023origins, and affect between 3% and 4% of births. Other rare …
-
List item
Press release: PRAC recommends strengthening the restrictions on the use of valproate in women and girls
PRAC, Last updated: 10/10/2014palate) compared to a 2 to 3% risk for children in the … palate) compared to a 2 to 3% risk for children in the …